Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

• Enrique M. Ocio,
• Sara Bringhen,
• Joaquin Martinez-Lopez,
• Jesus San-Miguel,
• Stefania Oliva,
• Paula Rodriguez-Otero,
• Nadia Le Roux,
• Yvonne Dong,
• Severine Doroumian,
• Sandrine Macé,
• Maria-Victoria Mateos

Affiliations

Enrique M. Ocio

1 Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain

Sara Bringhen

2 SSD Clinical Trials in Onco-Ematologia e Myeloma Multiplo, AOU Città della Salute e della Scienza di Torino, Italy

Joaquin Martinez-Lopez

3 Hematology, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense de Madrid, Spain

Jesus San-Miguel

4 University Clinic of Navarra, CCUN, Center for Applied Medical Research (CIMA), IDISNA, CIBERONC, Pamplona, Spain

Stefania Oliva

2 SSD Clinical Trials in Onco-Ematologia e Myeloma Multiplo, AOU Città della Salute e della Scienza di Torino, Italy

Paula Rodriguez-Otero

4 University Clinic of Navarra, CCUN, Center for Applied Medical Research (CIMA), IDISNA, CIBERONC, Pamplona, Spain

Nadia Le Roux

5 Altran, Neuilly Sur Seine, France, on behalf of Sanofi

Yvonne Dong

6 Sanofi, Bejing, China

Severine Doroumian

7 Sanofi, Montpellier, France

Sandrine Macé

8 Sanofi, Translational Medicine, Chilly-Mazarin, France

Maria-Victoria Mateos

9 University Hospital of Salamanca and Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain